NPPA fixes price caps for 12 anti-diabetic medicines

Drug price regulator National Pharmaceutical Pricing Authority (NPPA) on Monday said it has fixed the ceiling prices for 12 anti-diabetic generic medicines, including glimepiride tablets, glucose injection and intermediate acting insulin solution. In a tweet, the drug price regulator said, “To make it possible for every Indian to afford medical treatment against diseases like diabetes, NPPA has initiated a successful step by fixing the ceiling prices of 12 anti-diabetic generic medicines.”

These include glimepiride tablet of strength 1 mg, with ceiling price at Rs 3.6 per tablet, while that for 2 mg is Rs 5.72 per tablet.

The ceiling price of 1 ml glucose injection of 25 per cent strength has been fixed at 17 paise, while that of 1ml of insulin (soluble) injection of strength 40IU/ml is Rs 15.09.

Similarly, 1 ml of intermediate acting (NPH) solution insulin injection of strength 40 IU/ml has a ceiling price of Rs 15.09, and that of 1 ml of premix insulin 30:70 injection (regular NPH) injection of strength 40 IU/ml is also Rs 15.09.

NPPA further said the ceiling price of metformin immediate release tablet of strength 500 mg has been fixed at Rs 1.51 per tablet, while that of 750 mg strength is at Rs 3.05 per tablet and 1,000 mg strength at Rs 3.61 per tablet.

For metformin control release tablet of strength 1000 mg, the ceiling price is Rs 3.66 per tablet, NPPA said, adding the same for 750 mg strength is Rs 2.4 per tablet and Rs 1.92 per tablet for metformin control release tablet of strength 500 mg.

  • Related Posts

    NHS backs delayed‑release treatment for cystinosis

    Decision expands options for eligible patients NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis. The decision provides…

    Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

    Mumbai/Pune: In a major regulatory enforcement action aimed at safeguarding public health, the Maharashtra Food and Drug Administration (FDA) has permanently cancelled the Ayurvedic drug manufacturing licence of Pune-based M/s Inducare Pharma…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    NHS backs delayed‑release treatment for cystinosis

    NHS backs delayed‑release treatment for cystinosis

    Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

    Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

    Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

    Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

    Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

    Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

    Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

    Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

    AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care

    AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care